A citation-based method for searching scientific literature

Sandeep T Patil, Lu Zhang, Ferenc Martenyi, Stephen L Lowe, Kimberley A Jackson, Boris V Andreev, Alla S Avedisova, Leonid M Bardenstein, Issak Y Gurovich, Margarita A Morozova, Sergey N Mosolov, Nikolai G Neznanov, Alexander M Reznik, Anatoly B Smulevich, Vladimir A Tochilov, Bryan G Johnson, James A Monn, Darryle D Schoepp. Nat Med 2007
Times Cited: 783







List of co-cited articles
1452 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia.
Bruce J Kinon, Lu Zhang, Brian A Millen, Olawale O Osuntokun, Judy E Williams, Sara Kollack-Walker, Kimberley Jackson, Ludmila Kryzhanovskaya, Natalia Jarkova. J Clin Psychopharmacol 2011
174
33



Metabotropic glutamate receptors: physiology, pharmacology, and disease.
Colleen M Niswender, P Jeffrey Conn. Annu Rev Pharmacol Toxicol 2010
26

A Double-Blind, Placebo-Controlled Comparator Study of LY2140023 monohydrate in patients with schizophrenia.
AnnCatherine M Downing, Bruce J Kinon, Brian A Millen, Lu Zhang, Lin Liu, Margarita A Morozova, Ronald Brenner, Tami Jo Rayle, Laura Nisenbaum, Fangyi Zhao,[...]. BMC Psychiatry 2014
66
30

Targeting metabotropic glutamate receptors for novel treatments of schizophrenia.
James Maksymetz, Sean P Moran, P Jeffrey Conn. Mol Brain 2017
69
28

Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
J H Krystal, L P Karper, J P Seibyl, G K Freeman, R Delaney, J D Bremner, G R Heninger, M B Bowers, D S Charney. Arch Gen Psychiatry 1994
19

AZD8529, a positive allosteric modulator at the mGluR2 receptor, does not improve symptoms in schizophrenia: A proof of principle study.
Robert E Litman, Mark A Smith, James J Doherty, Alan Cross, Shane Raines, Lev Gertsik, Stephen R Zukin. Schizophr Res 2016
45
42

Metabotropic glutamate receptors: from the workbench to the bedside.
F Nicoletti, J Bockaert, G L Collingridge, P J Conn, F Ferraguti, D D Schoepp, J T Wroblewski, J P Pin. Neuropharmacology 2011
414
18

Identification of a serotonin/glutamate receptor complex implicated in psychosis.
Javier González-Maeso, Rosalind L Ang, Tony Yuen, Pokman Chan, Noelia V Weisstaub, Juan F López-Giménez, Mingming Zhou, Yuuya Okawa, Luis F Callado, Graeme Milligan,[...]. Nature 2008
560
17



Pomaglumetad Methionil (LY2140023 Monohydrate) and Aripiprazole in Patients with Schizophrenia: A Phase 3, Multicenter, Double-Blind Comparison.
David H Adams, Lu Zhang, Brian A Millen, Bruce J Kinon, Juan-Carlos Gomez. Schizophr Res Treatment 2014
46
32

Recent advances in the phencyclidine model of schizophrenia.
D C Javitt, S R Zukin. Am J Psychiatry 1991
14

Pomaglumetad methionil: no significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo.
Virginia L Stauffer, Brian A Millen, Scott Andersen, Bruce J Kinon, Lisa Lagrandeur, J P Lindenmayer, Juan Carlos Gomez. Schizophr Res 2013
75
18


Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder.
Eduardo Dunayevich, Janelle Erickson, Louise Levine, Ronald Landbloom, Darryle D Schoepp, Gary D Tollefson. Neuropsychopharmacology 2008
147
13


Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Jeffrey A Lieberman, T Scott Stroup, Joseph P McEvoy, Marvin S Swartz, Robert A Rosenheck, Diana O Perkins, Richard S E Keefe, Sonia M Davis, Clarence E Davis, Barry D Lebowitz,[...]. N Engl J Med 2005
13



In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders.
Linda M Rorick-Kehn, Bryan G Johnson, Karen M Knitowski, Craig R Salhoff, Jeffrey M Witkin, Kenneth W Perry, Kelly I Griffey, Joseph P Tizzano, James A Monn, David L McKinzie,[...]. Psychopharmacology (Berl) 2007
128
11

A selective positive allosteric modulator of metabotropic glutamate receptor subtype 2 blocks a hallucinogenic drug model of psychosis.
Michael A Benneyworth, Zixiu Xiang, Randy L Smith, Efrain E Garcia, P Jeffrey Conn, Elaine Sanders-Bush. Mol Pharmacol 2007
126
11

Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study.
Daniel Umbricht, Daniela Alberati, Meret Martin-Facklam, Edilio Borroni, Eriene A Youssef, Michael Ostland, Tanya L Wallace, Frédéric Knoflach, Ernest Dorflinger, Joseph G Wettstein,[...]. JAMA Psychiatry 2014
138
11

Decoding the signaling of a GPCR heteromeric complex reveals a unifying mechanism of action of antipsychotic drugs.
Miguel Fribourg, José L Moreno, Terrell Holloway, Davide Provasi, Lia Baki, Rahul Mahajan, Gyu Park, Scott K Adney, Candice Hatcher, José M Eltit,[...]. Cell 2011
194
11


CNS distribution of metabotropic glutamate 2 and 3 receptors: transgenic mice and [³H]LY459477 autoradiography.
Rebecca A Wright, Bryan G Johnson, Ce Zhang, Craig Salhoff, Ann E Kingston, David O Calligaro, James A Monn, Darryle D Schoepp, Gerard J Marek. Neuropharmacology 2013
66
15


A family of metabotropic glutamate receptors.
Y Tanabe, M Masu, T Ishii, R Shigemoto, S Nakanishi. Neuron 1992
948
10

Perspectives on the mGluR2/3 agonists as a therapeutic target for schizophrenia: Still promising or a dead end?
Meng-Lin Li, Xi-Quan Hu, Feng Li, Wen-Jun Gao. Prog Neuropsychopharmacol Biol Psychiatry 2015
40
25

Pharmacokinetic and pharmacodynamic characterisation of JNJ-40411813, a positive allosteric modulator of mGluR2, in two randomised, double-blind phase-I studies.
Hiba Salih, Ion Anghelescu, Iva Kezic, Vikash Sinha, Eef Hoeben, Luc Van Nueten, Heidi De Smedt, Peter De Boer. J Psychopharmacol 2015
32
31

Pharmacological agents acting at subtypes of metabotropic glutamate receptors.
D D Schoepp, D E Jane, J A Monn. Neuropharmacology 1999
878
10

Pharmacology and functions of metabotropic glutamate receptors.
P J Conn, J P Pin. Annu Rev Pharmacol Toxicol 1997
10

Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia.
P Jeffrey Conn, Craig W Lindsley, Carrie K Jones. Trends Pharmacol Sci 2009
267
10


HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity.
Mitsumasa Kurita, Terrell Holloway, Aintzane García-Bea, Alexey Kozlenkov, Allyson K Friedman, José L Moreno, Mitra Heshmati, Sam A Golden, Pamela J Kennedy, Nagahide Takahashi,[...]. Nat Neurosci 2012
177
10

The antipsychotic-like effects of positive allosteric modulators of metabotropic glutamate mGlu4 receptors in rodents.
Anna Sławińska, Joanna M Wierońska, Katarzyna Stachowicz, Marcin Marciniak, Magdalena Lasoń-Tyburkiewicz, Piotr Gruca, Mariusz Papp, Magdalena Kusek, Krzysztof Tokarski, Darío Doller,[...]. Br J Pharmacol 2013
36
27


Biased mGlu5-Positive Allosteric Modulators Provide In Vivo Efficacy without Potentiating mGlu5 Modulation of NMDAR Currents.
Jerri M Rook, Zixiu Xiang, Xiaohui Lv, Ayan Ghoshal, Jonathan W Dickerson, Thomas M Bridges, Kari A Johnson, Daniel J Foster, Karen J Gregory, Paige N Vinson,[...]. Neuron 2015
83
12


Glutamate receptor dysfunction and schizophrenia.
J W Olney, N B Farber. Arch Gen Psychiatry 1995
9

Selective actions of novel allosteric modulators reveal functional heteromers of metabotropic glutamate receptors in the CNS.
Shen Yin, Meredith J Noetzel, Kari A Johnson, Rocio Zamorano, Nidhi Jalan-Sakrikar, Karen J Gregory, P Jeffrey Conn, Colleen M Niswender. J Neurosci 2014
80
11

An mGlu5-Positive Allosteric Modulator Rescues the Neuroplasticity Deficits in a Genetic Model of NMDA Receptor Hypofunction in Schizophrenia.
Darrick T Balu, Yan Li, Shunsuke Takagi, Kendall Taylor Presti, Teniel S Ramikie, Jerri M Rook, Carrie K Jones, Craig W Lindsley, P Jeffrey Conn, Vadim Y Bolshakov,[...]. Neuropsychopharmacology 2016
41
21




Group II metabotropic glutamate receptor agonists and positive allosteric modulators as novel treatments for schizophrenia.
Matthew J Fell, David L McKinzie, James A Monn, Kjell A Svensson. Neuropharmacology 2012
72
12





Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.